(Total Views: 382)
Posted On: 07/30/2019 2:30:13 AM
Post# of 153802
Where has Soyunmorn obtained this information from? I've never seen a medical paper outlining the methodology of trial.
Was the supposed pretreatment with carboplatin, leronlimab, anthracyclines or taxane?
Although clinical testing may not be quite as spectacular as pre-clinical I think the highlighted section below proves out leronlimab.
The one potential negative would be that with a high tumor burden leronlimab may be overwhelmed by the number of CCR5 sites. But the CCR5 occupancy test will sort that out.
Was the supposed pretreatment with carboplatin, leronlimab, anthracyclines or taxane?
Although clinical testing may not be quite as spectacular as pre-clinical I think the highlighted section below proves out leronlimab.
The one potential negative would be that with a high tumor burden leronlimab may be overwhelmed by the number of CCR5 sites. But the CCR5 occupancy test will sort that out.
Quote:
("CytoDyn" or the "Company", a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announces that in a murine xenograft human breast cancer metastatic model, after 9 weeks, compared with untreated mice at 8 weeks, the leronlimab treated mice continued to have a >98% reduction in metastatic burden. Moreover, to test the ability of leronlimab to fight high tumor burden models, four of the mice in the control group with advanced metastatic disease, were treated with leronlimab. Two of these four mice were still alive at week 16.
(0)
(0)
